Company ProfilePremium

Thor Group Limited

Company Profile Analysis

ESOMAR 23 Corporate BadgeISO Certifications Badge
Thor Group Limited - Company showcase

Year Founded & Workforce

1959

500 Employees

Thor Group Limited logo

Thor Group Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Thor Group Limited Overview

THOR is a privately owned, UK-headquartered speciality chemicals group with nearly seven decades of history. It is one of the world's established independent producers of industrial biocides. Its Acticide® franchise preserves water-based paints, coatings, adhesives, polymer emulsions, detergents, fuels and many other products against microbial spoilage.

The group is vertically integrated into its own active substances, such as isothiazolinones, formaldehyde donors, IPBC and quaternary ammonium compounds. Around biocides it has built three adjacent businesses:

  • Disinfection

  • Personal Care, under the Microcare® preservatives brand

  • Performance Chemicals, including Aflammit® flame retardants and the newer Amaval™ multifunctional additives

With €642m of FY2025 turnover, a 19.2% EBITDA margin and €150m of cash, THOR differs from listed peers in three ways. It is debt-free, it pays out most of its earnings as dividends, and it runs a decentralised operating model across 14 operating units. Its main strategic exposures are EU regulation under the BPR and REACH, decorative-coatings demand, and raw-material-driven price competition.


Company's own description. In its FY2025 report, the group describes itself as focused on developing, manufacturing and supplying speciality chemical solutions to a diversified global customer base. It operates through a network of manufacturing sites, distribution sites and technical support centres, supported by central governance, finance, digital, procurement and R&D functions.

The holding company's stated role is to allocate capital, provide governance and leadership, and support strategy execution across its subsidiaries. The group's principal activity is "the manufacture and distribution of speciality chemicals" [TATO-25, Strategic and Directors' Reports].

The group's marketing describes THOR ingredients as everyday but invisible. They preserve washing-up liquids and detergents, protect furniture and clothing in the event of fire, and enhance moisturisers and shampoos [WEB / LinkedIn company profile].

Business model. THOR is a business-to-business ingredients manufacturer. It sells active substances and formulated additives, which customers dose at low concentrations into their own products. FY2025 business units [TATO-25]:

Revenue model. Revenue comes almost entirely from product sales: manufactured goods recognised on despatch. A small "rendering of services" component is associated with product sales [TATO-25, note 1.5]. There are no subscription or licensing revenues of any disclosed significance.

Technical service and microbiological testing are supplied through Technical Service Centres. These centres support sales but are not separately monetised in disclosed figures. Pricing is transactional and competitive. In FY2025 the group reported "continued downwards pressure on market pricing" amid falling raw-material prices, while volumes grew 4.1% [TATO-25].

Value-chain position. THOR sits in the middle of the chemicals value chain. It buys commodity and intermediate raw materials; the largest Scope 3 category is purchased chemicals and raw materials [TATO-25]. It synthesises its own biocidal actives at major sites; the company states isothiazolinones are available from "three major Thor sites" [WEB]. It then formulates finished additive blends.

Customers are formulators such as paint makers, adhesive producers, detergent and cosmetics brands, textile finishers and plastics compounders. Vertical integration into actives is a structural differentiator. In 2025 the group says added capacity reduced its "reliance on third party sourcing for key strategic actives" [TATO-25].

Customer types and end-markets [WEB product pages; TATO-25; CB Insights]:

  • Paints, plasters and decorative coatings. This is the largest single reference market cited in the annual report.

  • Polymer emulsions, adhesives and sealants.

  • Construction and concrete; minerals and slurries.

  • Household products, detergents and wet wipes.

  • Metal-working fluids, fuels, water treatment, and pulp and paper.

  • Plastics and wood-plastic composites (WPC); textiles and leather.

  • Cosmetics, toiletries and personal care.

  • Institutional, industrial and healthcare disinfection, including dialysis-centre applications featured in company news [WEB].

  • Flame-retardant applications in textiles, furniture and plastics.

Independent characterisation. THOR is a mid-sized, family-heritage, regulation-intensive niche player. Its economic moat comes from three things:

  1. The cost and duration of maintaining biocide active-substance registrations (EU BPR, UK BPR, US EPA, Mexico COFEPRIS).

  2. Captive active-substance manufacturing.

  3. Technical-service intimacy with formulators.

Its financial profile is that of a mature, cash-generative industrial business. Revenue has been flat to slightly down since 2022 (FY2022 €688.9m to FY2025 €641.9m). Margins recovered after a 2023 destocking trough, there is no financial debt, and payout ratios run at 80–95% of net profit. Growth is being pursued organically through capacity (the €18m Speyer Building 4) and adjacencies (Personal Care, Disinfection, Performance Chemicals), rather than by acquisition.

Strategy

Stated strategy themes [TATO-25].

The board's six strategic priorities for 2025:

  1. Protecting and enhancing gross margins through pricing discipline, manufacturing efficiency and procurement optimisation.

  2. Maintaining operational resilience and supply-chain reliability.

  3. Disciplined control of fixed costs and headcount growth.

  4. Targeted investment in technology, capacity and regulatory capability.

  5. Maintaining a strong balance sheet and liquidity.

  6. Delivering the 2030 Strategy plan (2025–2030 Strategic Plan, presented to the Main Board in Q1 2025).

The board also describes the business model as "rooted in innovation, quality, and exceptional customer service". It says it continues to review "organic development and selective acquisition opportunities" while staying cautious on the macro outlook. Its forward focus is "capital discipline, portfolio optimisation" and long-term growth, resilience and shareholder value.

Strategic initiatives, last 24 months (Oct 2024 – Oct 2026):

Medium-term financial targets and guidance: not publicly disclosed. No numeric guidance is published. Management states it has produced FY2026 cash-flow forecasts and believes the group is "well positioned to continue to execute its strategy, invest selectively for growth, and meet its obligations" [TATO-25]. Dividend policy is kept under review "in line with its investment plans" [TATO-25].

Products & Services

Pricing models are not publicly disclosed for any product. Products are sold B2B on negotiated or list pricing.

Biocides (Acticide®)

Product line / applicationDescription & capabilitiesTarget customerYear / statusSource
Acticide® (umbrella brand)International trademark for THOR biocides based on own-manufactured actives: isothiazolinones, formaldehyde donors, IPBC and quats. Protects products in wet/fluid, dry/cured and intermediate statesFormulators across industriesTrademark first registered 1966[WEB]
Paint & plaster wet-state biocidesIn-can preservation of water-based decorative paints and plastersPaint and coatings manufacturersCurrent[WEB biocides page]
Dry-film biocides with AMMEAdvanced Micro Matrix Embedding encapsulation protects film-preservative actives, giving controlled release and lower leachingFaçade coatings, plasters, sealantsAMME registered 2011[WEB]
Polymer emulsion biocidesPreservation of binders and emulsions during manufacture and storageEmulsion and polymer producersCurrent[WEB]
Water treatment / pulp & paper biocidesSlime and microbial control in process waterPaper mills, water treatersCurrent[WEB]
Plastics & WPC biocidesAntimicrobial protection for plastics and wood-plastic compositesCompoundersCurrent[WEB]
Metal-working fluid biocidesTank-side and in-concentrate preservationMWF formulatorsCurrent[WEB]
Adhesives & sealants biocidesIn-can and dry-film protectionAdhesive manufacturersCurrent[WEB]
Textile biocidesAntimicrobial finishingTextile millsCurrent[WEB]
Fuel biocidesMicrobial contamination control in fuelsFuel distributors and usersCurrent[WEB]
Construction & concrete biocidesProtection of admixtures and construction chemicalsConstruction chemicals producersCurrent[WEB]
Minerals & slurries biocidesPreservation of mineral slurries (e.g. calcium carbonate, kaolin)Mineral processorsCurrent[WEB]
Household & detergent biocidesIn-can preservation of detergents and cleanersHome-care brandsCurrent[WEB]
Wet-wipe biocidesPreservation of wipe lotionsWipe manufacturersCurrent[WEB]
Leather biocides (Acticide® WB range)Preservation in beamhouse and tanning processes; historically distributed via a TFL partnershipTanneriesPartnership date undisclosed[Leather International]
High-purity isothiazolinonesStabilised high-purity actives with acceptance by US EPA and FDA; supported through the EU BPRRegulated marketsCurrent[WEB legacy biocides page]

Disinfection

Product lineDescriptionTarget customerSource
Quaternary-ammonium-based disinfectants (Acticide® BAC and related)Quats manufactured by THOR for hard-surface and institutional disinfection. Speyer holds an environmental permit for Acticide BAC productionInstitutional cleaning, healthcare and household formulators[WEB; Speyer permit record]
Healthcare / dialysis applicationsCompany news features THOR solutions supporting dialysis care across 11 centres in Malaysia (date not disclosed)Healthcare operators[WEB News]

Personal Care

Product lineDescriptionTarget customerYearSource
Microcare®Preservatives and antimicrobial ingredients for cosmetics, toiletries and personal care productsCosmetics and personal care brandsTrademark granted 1999[WEB; ipqwery]
Emulsifiers / emollientsListed in THOR trademark specifications for cosmetic chemical productsCosmetic formulatorsCurrent[ipqwery]

Performance Chemicals

Product lineDescriptionTarget customerYearSource
Aflammit®Flame retardants for textiles, furniture and plastics; heritage from the 1972 Dr Quehl acquisitionTextile finishers, plastics compoundersTrademark filed 1998[WEB]
FR-Plastics business lineFlame retardants dedicated to plastics, run as a global business linePlastics industryCurrent[theorg.com org chart]
Amaval™ multifunctional additivesMultifunctional additives (no further specifications disclosed)Coatings and formulatorsLaunched 2024[WEB History]
Advansil / THOR SiliconesSilicone-based chemicals trademarkIndustrial usersDate not disclosed[ipqwery]

Services

ServiceDescriptionSource
Technical Service CentresMicrobiological testing, application support and regulatory support[WEB; Prospeo company description]
Regulatory supportDossier support for BPR, REACH, EPA and COFEPRIS registrations[TATO-23; WEB]
Product Carbon Footprint (PCF) dataPCF methodology developed in 2025; data shared with customers through the SiGreen exchange[TATO-25]

Financial Narrative

Coverage: Tato Holdings Limited consolidated accounts under UK GAAP (FRS 102), in EUR thousands.

  • FY2022–FY2023 figures: [TATO-23]

  • FY2024–FY2025 figures: [TATO-25]

"Derived" rows are analyst calculations from reported figures. Per-share metrics use about 10.38m shares, inferred because total dividends ÷ DPS equals 10,380k shares in every year.

Income statement

EPS: diluted EPS is not reported (unlisted; no dilutive instruments disclosed).

DPS composition:

Margins and growth

Effective tax rate: FY2022 and FY2023 are the "underlying" rates reported in [TATO-23]. FY2024 and FY2025 are as reported in [TATO-25].

Reported turnover growth: FY2022 is organic growth as reported in [TATO-23]. FY2023 is derived (the company reports −7% organic and −5.2% at constant currency). FY2024 is organic growth per the [TATO-25] KPI table. FY2025 is as reported (+1.1% at constant currency).

Organic volume growth: FY2023 is the KPI figure; the narrative also gives −4.3%.

Revenue CAGR FY2022–FY2025 (derived): −2.3% per year: The decline reflects price normalisation after the 2022 inflation spike and euro translation effects. Volumes over the same period went −4%, +8%, +4.1%, a cumulative increase of roughly 8%.

Commentary.

FY2022 was a price-led peak: Turnover reached €688.9m with 14% organic growth despite a 7% volume decline. Selling-price inflation more than offset lost tonnage, and EBITDA margin hit 20.4%.

FY2023 was the trough: Customers destocked and raw-material deflation passed through to selling prices. Turnover fell to €642.4m, gross margin compressed to 29.4% and EBITDA margin fell to 16.4%. Operating profit fell 31.5% to €83.2m.

FY2024 brought a volume-led recovery: Volumes rose 8%. Operating profit rose to €99.9m even after two one-offs:

  • €13.3m of South Africa historical clean-up costs

  • €1.6m of Turkish hyperinflation effects

FY2025 showed underlying margin resilience: Reported turnover was down 1.1% because of the weaker US dollar, but constant-currency turnover was up 1.1%. Gross margin improved to 37.0% from pricing discipline, lower material costs, mix and better capacity utilisation. Operating profit slipped 1.5%. Reported overheads rose only 1.2%, but the FY2024 base included the one-offs; excluding them, overheads rose 16.5%. Drivers of that increase:

  • Unrealised FX losses in Mexico

  • Wage inflation and investment in people

  • Higher depreciation

  • Impairments in Mexico and France

  • A new slow-moving stock provisioning policy

The lower effective tax rate (27.2%) lifted net profit 8.9% to €76.9m [TATO-25].

Balance sheet

Total assets (derived): fixed assets plus current assets.

Goodwill: none is shown on the face of the balance sheet. Intangibles are acquired software and capitalised third-party product registration costs [TATO-25 note 1.8].

Debt. No bank borrowings are presented on the face of the balance sheets reviewed. Interest payable was only €120k in FY2024 and €170k in FY2025, consistent with negligible debt. The group says it uses overdrafts and short-term loans "when required" [TATO-25].

  • Total debt (short/long split): not separately disclosed; immaterial.

  • Net debt: negative, i.e. a net cash position of about €149.6m at FY2025 (€170.1m at FY2024).

  • The content of "creditors due after more than one year" (€4.6m) was not itemised in the extract.

Cash flow

  • Net cash from operating activities is after tax and interest received.

  • FY2025 capex was €28.6m tangible plus €4.0m intangible; the company reports €32.6m invested in fixed assets.

  • No share buybacks are disclosed.

Commentary. Cash flow is dominated by working capital:

FY2022: operating cash conversion was weak (€46.0m) because the group built inventory to €219.9m, or 210 stock days, during supply-chain disruption.

FY2023: destocking released about €63m of inventory. Operating cash flow reached €140.3m, a 138% cash conversion ratio per [TATO-23], and cash rose to €156.9m.

FY2024–FY2025: inventories were deliberately rebuilt to support service levels, rising to €164.2m (143 days).

FY2025 tax: tax paid rose 50% to €34.5m. Together with the higher dividend of €72.7m and capex of €32.6m, this produced the first net cash outflow in the period, €18.6m before FX. The company says it "expended €20,413,000 cash in 2025".

Ratios

ROIC: is approximated with no debt, using NOPAT = operating profit × (1 − effective tax rate).

Debt to equity: is about zero, since no borrowings were identified.

Net debt to EBITDA: is negative because the group holds net cash.

Cash conversion cycle: creditor days are not disclosed, so the full cycle cannot be computed. Stock days plus debtor days were:

Commentary. Returns are moderate (ROE 10–15%) rather than high, held down by a very large, under-levered equity base. Equity is €639m against €150m of cash and only €61m of short-term creditors. On a cash-adjusted basis (ROIC about 14–17%), the operating business earns attractive returns.

The working-capital intensity, at more than 200 days of stock plus debtors, is structurally high. The board treats it as a deliberate service strategy: holding "high levels of strategic inventories" to protect customers against supply disruption [TATO-25]. Debtor days have crept up from 57 to 72 over three years, which merits monitoring.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Business Units

Business unit (as named in FY2025 report)Contents (from company product pages)FY2025 directional performance [TATO-25]

Biocides (Industrial Biocides)

Acticide® in-can, wet-state and dry-film preservatives; isothiazolinones (MIT, BIT, CMIT/MIT, OIT/DCOIT families), formaldehyde donors, IPBC, AMME-encapsulated dry-film biocides; applications in paints, plasters, emulsions, adhesives, fuels, MWF, water treatment, pulp and paper, plastics/WPC, textiles, leather, construction, slurries, household and wet wipes

Broadly flat, with regional variations

Disinfection

Quaternary ammonium compound (quat) based disinfectant actives and formulations, e.g. the Acticide® BAC range permitted at Speyer; healthcare and institutional applications

Grew year on year

Personal Care

Microcare® preservatives and ingredients for cosmetics, toiletries and personal care; emulsifiers and emollients (per trademark specifications)

Grew year on year

Performance Chemicals

Aflammit® flame retardants (textiles, plastics; the "FR-Plastics" business line appears in org-chart data); Amaval™ multifunctional additives (2024); Advansil silicones trademark

Grew year on year

Revenue by Segment

MetricFY2022FY2023FY2024FY2025

Group turnover (EUR K)

688,906642,380648,974641,878

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025

Turnover (EUR K)

688,906642,380648,974641,878

Gross profit (EUR K)

226,468188,808237,415237,365

Operating profit (EUR K)

121,42383,17999,92998,440

Depreciation and impairment of tangibles (EUR K)

17,89221,07921,11823,140

Amortisation of intangibles (EUR K)

1,2841,4151,5861,838

EBITDA, derived as operating profit plus D&A (EUR K)

140,599105,673122,633123,418

Profit before tax (EUR K)

123,45288,220106,812105,616

Tax charge (EUR K)

30,61723,36236,19728,712

Profit after tax (EUR K)

92,83564,85870,61576,904

EPS basic, derived (EUR)

8.946.256.807.41

Dividends per share declared and paid (EUR)

6.005.005.507.00

Dividend History

Fiscal yearPaymentsTotal DPS

FY2022

€3 in March + €3 in December

€6.00

FY2023

€2 in April + €3 in October

€5.00

FY2024

€2 in April + €3.50 in October

€5.50

FY2025

€3 in April + €4 in October

€7.00

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025

Gross margin, as reported (%)

32.929.436.637.0

EBITDA margin, company-reported (%)

20.416.418.919.2

Operating margin, derived (%)

17.612.915.415.3

Pre-tax margin, derived (%)

17.913.716.516.5

Net margin, derived (%)

13.510.110.912.0

Effective tax rate (%)

24.826.533.927.2

Reported turnover growth (%)

14.0-6.81.0-1.1

Organic volume growth (%)

-7.0-4.08.04.1

Balance Sheet

MetricFY2022FY2023FY2024FY2025

Intangible assets (EUR K)

3,3843,4533,8875,975

Tangible assets (EUR K)

280,483283,138283,124281,690

Stocks (EUR K)

219,897157,011162,407164,154

Trade and other debtors (EUR K)

125,771125,059120,210126,487

Cash and cash equivalents (EUR K)

89,620156,933170,076149,620

Total assets, derived (EUR K)

719,155725,594739,704727,926

Creditors due within one year (EUR K)

63,42256,19159,97861,256

Creditors due after one year (EUR K)

2,1034,0004,1904,557

Provisions for liabilities (EUR K)

23,20017,78625,31423,199

Net current assets (EUR K)

371,866382,812392,715379,005

Shareholders' funds (EUR K)

630,430647,617650,222638,914

Goodwill (EUR K)

0000

Cash Flow and Returns & Leverage Ratios (%)

MetricFY2022FY2023FY2024FY2025

Operating cash flow before working capital (EUR K)

133,346102,621126,747122,482

Net cash from operating activities (EUR K)

45,959140,27497,24086,579

Capital expenditure, tangible plus intangible (EUR K)

29,52521,90126,05632,592

Free cash flow, derived as OCF minus capex (EUR K)

16,434118,37371,18453,987

Dividends paid (EUR K)

62,28051,90057,09072,660

Share buybacks (EUR K)

0000

Tax paid (EUR K)

——23,02934,453

Dividend payout ratio, derived (%)

67.180.080.894.5

Returns & Leverage Ratios (%) and Financial Ratios (x)

Ratio (derived)FY2022FY2023FY2024FY2025

ROE on closing equity (%)

14.710.010.912.0

ROA on closing total assets (%)

12.98.99.510.6

ROIC, NOPAT over (equity minus cash) (%)

16.912.513.814.6

Current ratio (x)

6.867.817.557.19

Debt to equity (x)

0000

Net debt to EBITDA (x)

-0.64-1.49-1.39-1.21

Interest coverage, operating profit over interest payable (x)

——833579

Asset turnover (x)

0.960.890.880.88

Average stock days, company KPI

210145136143

Average trade debtor days, company KPI

57606872

Working Capital (Days)

MetricFY2022FY2023FY2024FY2025

Stock days plus debtor days

267205204215

Revenue by Region

RegionFY2023FY2024FY2025

Group turnover (EUR K)

642,380648,974641,878

Region Overview

RegionFY2025 commentaryAssessment

APAC

Strongest volume growth, driven primarily by new business wins

Fastest-growing region by volume. Supported by the China (Zhenjiang) manufacturing hub, India subsidiary (2023), new South Korea branch (2025) and Malaysia plant renovation

Americas

Strong first half; demand softened in H2 2025; USD translation was a material headwind; Mexico had FX losses and impairments

Volume positive but reported-euro contribution weakened. US tariffs prompted the group to rebalance production across its global footprint

EMEA

Contributed volume growth, but conditions stayed challenging, with pressure in construction-related markets and persistent price competition, partly offset by mix

The weakest region on pricing. Decorative coatings volumes −0.2% and revenues −0.9% globally in 2025

Capital Markets

ItemStatus

Share price performance (1/3/5-year)

Not applicable: unlisted; no traded price

Valuation multiples (P/E, EV/EBITDA, EV/Sales, P/B)

Not applicable / not publicly disclosed

Book-value reference

Shareholders' funds €638.9m at FY2025, about €61.55 per share (derived, about 10.38m shares)

Analyst consensus

None; no sell-side coverage

Credit ratings (Moody's / S&P / Fitch)

None; no rated debt

Debt maturity profile

Not applicable: no bank borrowings identified; creditors due after one year €4.6m (composition not itemised)

Buyback authorisations

None disclosed. A capital redemption reserve of €250k indicates a historical share repurchase or redemption

Dividend policy

No formal policy published. Interim dividends paid twice a year; the board reviews dividends "in line with its investment plans and business objectives" [TATO-25]

Per-Share Data and Dividends & Capital Returns

MetricFY2022FY2023FY2024FY2025

Dividend per share (EUR)

6.005.005.507.00

Total dividends paid (EUR K)

62,28051,90057,09072,660

Payout ratio of profit after tax (%)

67.180.080.894.5

Dividend as share of opening cash (%)

—69.536.442.7

Analyst Conclusions

Management guidance. No quantitative guidance is published. Management says:

  • The group is well positioned to execute strategy and "invest selectively for growth".

  • FY2026 cash-flow forecasts support going concern.

  • The focus is on capital discipline, portfolio optimisation, and selective organic and inorganic opportunities [TATO-25].

Consensus expectations: none (no analyst coverage).

Bull case:

  1. Operating leverage from volume. Volumes have grown in consecutive years (+8% in FY2024, +4.1% in FY2025) while gross margin expanded to 37.0%. Once pricing stabilises as raw-material deflation runs its course, the 40,000 t Speyer expansion could translate volume into reported revenue growth and margin above 20% EBITDA.

  2. Balance-sheet optionality. €149.6m of net cash and no debt allow the group to keep its €70m-plus annual dividend, fund capex of about €30m, and pursue selective acquisitions at once. As one of the last scaled independent biocide makers, it could also attract strategic interest.

  3. Adjacency mix shift. Disinfection, Personal Care and Performance Chemicals all grew in FY2025, APAC delivered the strongest growth, and Amaval is a new platform. Together these diversify the group away from cyclical EMEA decorative coatings.

Bear case:

  1. Structural price deflation. Turnover is 6.8% below FY2022 despite higher volumes. Asian competition and raw-material pass-through may keep eroding average selling prices.

  2. Regulatory concentration. A large share of the portfolio rests on isothiazolinones and formaldehyde donors under tightening EU CLP, BPR and REACH regimes. A reclassification or non-renewal could strand capacity.

  3. Cost and capital drag. Underlying overheads rose 16.5% in FY2025, debtor days rose to 72, and stock days are 143. A 94.5% payout leaves a thin buffer: cash already fell €20m in FY2025 even before any 2026 shocks from the Middle East conflict, energy costs or FX.

Catalysts and monitorables (next 12 months):

  • FY2026 accounts (expected around May 2027): whether Speyer volumes lift turnover above €650m, and whether the EBITDA margin holds at or above 19%.

  • Q3 2026 decision on a science-based target, and the climate KPIs to follow.

  • Any acquisition announcement drawing on the cash pile.

  • USD/EUR movements and tariff developments affecting the Americas.

  • Energy and logistics effects of the Middle East conflict.

  • EU regulatory decisions on isothiazolinone and quat active-substance renewals.

  • Trends in debtor days and stock days.

  • Changes in dividend cadence.

  • Filing of Thor Group Limited's FY2025 small-company accounts (due 30 September 2026).

Analyst verdict. THOR, operating legally through Thor Group Limited and consolidated under Tato Holdings Limited, is a disciplined, conservatively financed, family-heritage speciality chemicals business. On cash returns and resilience it compares well with many listed peers. On top-line momentum and transparency it compares poorly.

The FY2025 accounts show the group's core competence: holding gross margin at 37% and EBITDA margin at 19.2% in a year when its largest end-market, decorative coatings, contracted and selling prices fell. Captive active-substance production and a decentralised, service-intensive model underpin that resilience, and the €18m Speyer expansion signals confidence in volume growth.

The weaknesses are equally clear. Reported revenue has drifted down for three years, to a 2.3% compound decline since the FY2022 inflation peak. Overheads are growing faster than gross profit, and working capital consumes more than 200 days of sales in stock and receivables. The capital-allocation stance has become notably shareholder-friendly. The FY2025 payout of 94.5% of earnings, combined with higher tax payments and capex, produced the first year of net cash outflow in the period. That is sustainable from a €150m cash pile, but not indefinitely unless earnings grow.

For counterparties, THOR is a low-credit-risk, financially robust supplier. Its exposure lies in regulation and pricing, not solvency. For potential acquirers or investors, its scale (about €640m revenue), regulatory estate and independence make it one of the few remaining mid-sized biocide assets globally.

The main monitorables:

  • Whether Speyer and APAC growth convert volume gains into revenue growth.

  • Whether management delivers on its newly formalised climate targets.

  • Whether the "selective acquisition" language becomes action.

Overall assessment: financially strong, strategically steady, growth-constrained. Its outlook is stable, with balance-sheet-driven upside optionality.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameNationalityRole (from website / report)Tenure / backgroundSource

David A. Hewitt

British

Group CEO; director

Nearly 40 years at THOR; on the Executive Board for almost 30 years; Group CEO since 2020; oversaw construction of the Wincham site (2001). Also a director of Thor Group Limited

[WEB Exec Board; TATO-25; CH]

P. J. (Philip) McDonald

British

Group CFO

Joined 2022 from senior finance roles at NSG Pilkington and the Hempel Group. Responsible for Finance, Procurement and Digital; member of the Audit & Risk, Ethics and Budget committees

[WEB; TATO-25]

P. (Peter) Hahn

German

Chief Sales Officer

Board member since 2007 (industrial biocides); CSO since 2019 with global commercial responsibility

[WEB; TATO-25]

Q. (Qinglin) Zheng

Chinese

Executive director, APAC

Joined THOR China in 2016; PhD in Chemistry; based in Zhenjiang; responsible for China, Malaysia, Australia and Japan

[WEB; TATO-25]

R. Baum

German

Executive director

Exec Board page refers to a member who completed a chemical engineering degree in the 1990s and became Head of R&D for biocides at THOR Germany. Attribution to R.

[WEB; TATO-25]

G. De Lucia

Italian

Executive director

—

[TATO-25]

D. Siroky

American

Executive director

—

[TATO-25]

I. Lobley

British

Non-Executive Director

Shareholder representative

[TATO-25]

A. (Albert) Sanders-Champney

British

Non-Executive Director

Appointed 30 Jun 2023, replacing Kevin Howes; shareholder representative

[TATO-23; TATO-25]

S. (Simon) Pearson

British

Company Secretary

Also director and secretary of Thor Group Limited

[TATO-25; CH]

Governance Overview

FeatureDetail

Board size

9: 7 executive and 2 non-executive directors

Independence

The two NEDs represent the primary shareholders, so neither is independent in the listed-company sense. No independent directors are disclosed

Chair / CEO separation

The identity of the chair is not disclosed

Committees

Audit & Risk (met twice in 2025); Ethics & Compliance; Remuneration & Nomination; Sustainability (formed early 2026, first meeting May 2026)

Other bodies

Executive Board (7 members from Europe, China and the USA); Budget Committee

Board agenda conventions

Health & Safety is the first substantive item at every Board meeting. ESG is a standing item twice a year. Cyber is a rolling item at every Main Board meeting

Board & Management Changes

DateChange
2020

David Hewitt becomes Group CEO

2022

Philip McDonald joins as Group CFO

30 Jun 2023

Kevin Howes (NED) resigns; Albert Sanders-Champney appointed

2023

New Heads of Digital, Audit & Risk, and Financial Planning & Analysis appointed

Apr 2024

Head of Group Audit & Risk Management and Group Digital Communications & Content Manager join

Q1 2026

Group Head of Sustainability recruited

Competitive Landscape

Competitors by Segment

SegmentCompetitorOwnershipRelative positioning vs. THOR

Industrial biocides

LANXESS (Material Protection Products, incl. ex-IFF/Dow Microbial Control acquired 2022)

Listed (Germany)

Largest global biocides portfolio after the acquisition; broader actives slate. THOR is smaller but independent and focused

Industrial biocides

Arxada (ex-Lonza Specialty Ingredients, incl. Troy Corp, acquired 2022)

Private-equity owned

Strong in dry-film and wood/material protection, where it overlaps with THOR's AMME dry-film range

Industrial biocides

Vink Chemicals

Private (Germany)

Mid-sized biocide specialist; direct competitor in coatings preservation

Industrial biocides

Chinese isothiazolinone producers (various)

Private / listed China

Price competition in commodity isothiazolinones, a source of FY2025 pricing pressure

Disinfection

Lonza / Arxada, LANXESS, Stepan, Ecolab (formulated disinfectants)

Mixed

Quat actives and formulated disinfection; THOR is a niche quats producer

Personal care preservatives

Ashland, Symrise, Schülke & Mayr, LANXESS, Clariant

Listed / private

Larger cosmetic-ingredient portfolios; THOR's Microcare is a niche preservative play

Flame retardants

ICL, Clariant (Exolit), Albemarle, LANXESS

Listed

Much larger FR producers; THOR's Aflammit is focused on textiles and plastics niches

Industrial biocides / cleaning (UK niche)

Chela, Oxi-Tech Solutions, Anolytech, Goldshield (per CB Insights)

Private

Small UK disinfection players; marginal overlap

Distribution-led competitors

IMCD, Brenntag (as channels for rival actives)

Listed

Distribute competitors' products; also potential partners

Competitor Detail

MetricTHOR (FY2025)

Revenue (EUR Mn)

641.9

Revenue growth (%)

-1.1

EBITDA margin (%)

19.2

Net cash (EUR Mn)

149.6

Recent Developments

THOR is private and publishes limited news, so several entries come from the FY2025 annual report and are dated at quarter or year level.

Company Snapshot

$723.7M

Revenue

500

Employees

1959

Founded

Bramling, New Zealand

Headquarters

SWOT Analysis

Strengths

  • Net cash and zero financial debt. Cash was €149.6m at FY2025 and interest payable only €170k [TATO-25].
  • Margin resilience. FY2025 gross margin was 37.0% (FY2024: 36.6%) and EBITDA margin 19.2% (18.9%), even with pricing pressure [TATO-25].
  • Volume outperformance. Volumes grew 4.1% in FY2025 while decorative coatings volumes fell 0.2% [TATO-25].
  • Vertical integration into actives. Isothiazolinones are made at three major sites, and added 2025 capacity reduced third-party sourcing [WEB; TATO-25].
  • Strong operating cash generation. Cumulative operating cash flow was €370m over FY2022–FY2025, funding €244m of dividends and €110m of capex [TATO-23; TATO-25].
  • ESG credentials. EcoVadis Gold (2025), ISO 45001 at all main sites, a third TCFD report, and a Scope 3 inventory of 427,230 tCO2e [TATO-25].
  • Management continuity. The CEO has nearly 40 years at THOR and the CSO has been on the board since 2007 [WEB].

Weaknesses

  • Top-line stagnation. Revenue fell from €688.9m in FY2022 to €641.9m in FY2025, a CAGR of −2.3% [TATO-23; TATO-25].
  • High working-capital intensity. Stock days were 143 and debtor days 72 in FY2025, and debtor days have risen from 57 in FY2022 [TATO-23; TATO-25].
  • Rising overheads. Underlying overheads rose 16.5% in FY2025 excluding FY2024 one-offs [TATO-25].
  • Limited transparency. There is no segment or geographic disclosure in public narrative, and the FRS 102 exemption is taken for key management compensation [TATO-25].
  • Legacy environmental liabilities. The group took €13.3m of South Africa clean-up costs in FY2024 and carries provisions of €23.2m at FY2025 [TATO-25].
  • FX exposure without a hedging policy. The group's stated policy is not to hedge, and translation losses hit OCI by €12.2m in FY2025 and €9.7m in FY2024 [TATO-25].

Opportunities

  • Speyer capacity. Building 4 adds up to 40,000 t of capacity for preservatives and flame retardants [WEB News].
  • APAC growth. APAC was the strongest-growing region in FY2025 on new business wins, supported by the India and South Korea expansion [TATO-25].
  • Growing adjacencies. Disinfection, Personal Care and Performance Chemicals all grew in FY2025, and Amaval launched in 2024 [TATO-25; WEB].
  • Sustainable-product demand. The group flags lower-carbon formulations as its leading climate opportunity, and PCF capability is already built [TATO-25].
  • Acquisition capacity. The debt-free balance sheet supports the "selective acquisition opportunities" under board review [TATO-25].
  • Channel optimisation. The Algol partnership expands reach into more than 3,000 Nordic and Baltic industrial customers [WEB News].

Threats

  • Pricing pressure. Raw-material deflation and competition put "continued downwards pressure on market pricing" in FY2025 [TATO-25].
  • Regulatory tightening. BPR and REACH regimes govern many products, and the group lists regulation as a principal risk [TATO-25].
  • Trade and geopolitics. Risks include US tariffs, "escalating military interventionism", and the Middle East conflict disclosed as a 2026 post-balance-sheet event [TATO-25].
  • Currency. Euro strength against the USD cost €14.4m of reported turnover in FY2025 [TATO-25].
  • Cyber. Ransomware and cyber security is the first-listed principal risk [TATO-25].
  • Climate costs. Carbon pricing and CBAM, logistics decarbonisation pass-through, and water stress at the Brazil, Spain and Malaysia sites [TATO-25].

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Q1 2025Main Board signs off the 2030 ESG Strategy [TATO-25]Shift from ESG strategy design to implementation
Q1 20252025–2030 Strategic Plan presented to the Main Board [TATO-25]Frames capex and portfolio priorities
Apr 2025Interim dividend of €3.00 per share paid [TATO-25]Higher than April 2024 (€2.00)
2025 (H1)Strong Americas demand; Mexico hedges USD exposure over 10 months (+€2.55m) [TATO-25]Rare use of hedging under CFO authority
2025US tariff escalation; production rebalanced across the global footprint to mitigate [TATO-25]Demonstrates multi-hub supply resilience
2025South Korea branch office opened [TATO-25; WEB]APAC expansion
2025Additional manufacturing capacity comes online for key actives [TATO-25]Reduces third-party sourcing; margin benefit
2025EcoVadis Gold awarded [TATO-25]ESG credential for coatings and personal-care customers
2025All main manufacturing sites achieve ISO 45001 [TATO-25]Health & safety governance
2025ISO 27001/NIS2-aligned ISMS roll-out; global M365 roll-out [TATO-25]Cyber is the top-listed principal risk
2025Group-wide Product Carbon Footprint methodology developed; SiGreen joined [TATO-25]Customer Scope 3 enablement
2025Financial-crime risk assessment under the UK Economic Crime and Corporate Transparency Act [TATO-25]Compliance readiness
2025Turkish hyperinflation accounting requirement removed; group does not recalculate (immaterial) [TATO-25]Accounting simplification
2025Asset-utilisation review; write-downs of surplus assets in Mexico and France [TATO-25]One-off cost pressure on overheads
2025New group inventory-provisioning policy for slow-moving stock [TATO-25]Raises provisions; tighter governance
2025Employee engagement survey (bi-annual; response rate typically above 75%) [TATO-25]People-risk mitigation
Oct 2025Interim dividend of €4.00 per share paid; FY2025 total €72.66m [TATO-25]Payout ratio about 94.5% of FY2025 profit
H2 2025Americas demand softens [TATO-25]Slower H2 momentum
FY2025Turnover €641.9m (−1.1% reported, +1.1% constant currency); volumes +4.1%; EBITDA margin 19.2%; PBT €105.6m; profit after tax €76.9m [TATO-25]Margin resilience in a contracting coatings market
Q1 2026Group Head of Sustainability recruited [TATO-25]ESG governance build-out
Early 2026Sustainability Committee formed (first meeting May 2026) [TATO-25]Fourth board committee
Early 2026Armed conflict in the Middle East disclosed as a non-adjusting post-balance-sheet event (supply chain, energy, FX risk) [TATO-25]Watch-item for 2026 costs
16 Mar 2026Production begins at THOR GmbH Building 4, Speyer (€18m; +40,000 t) [WEB News]Largest disclosed recent capacity investment
1 May 2026Algol Chemicals takes over Baltic distribution (Finland from 1 Jun 2026) [WEB News]Nordic and Baltic channel reset
20 May 2026FY2025 accounts approved by the board; clean audit opinion from Forvis Mazars [TATO-25]Annual reporting
Q2 2026 (planned)Launch of global Climate & Energy Taskforce [TATO-25]Decarbonisation execution
29 Jun 2026Thor Group Limited confirmation statement made up (next due 13 Jul 2027) [companiesintheuk]Statutory filing
Q3 2026 (expected)Decision on near-term science-based emissions targets [TATO-25]–
Undated (2025/26)THOR Malaysia celebrates plant and technical-centre renovation; dialysis disinfection reference across 11 Malaysian centres [WEB News]APAC investment and healthcare disinfection traction

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

3 charts
Income Statement: Revenue & Gross Profit: Turnover fell from EUR 688.9 Mn in FY2022 to EUR 641.9 Mn in FY2025.
Thor Group Limited — Income Statement: Revenue & Gross Profit
Series (EUR Mn)FY2022FY2023FY2024FY2025
Turnover688.9642.4649641.9
Gross profit226.5188.8237.4237.4

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.